-
Mashup Score: 6
AZALEA-TIMI 71 was halted due to the clear win for the factor XI/Xia inhibitor; control group patients have the option to switch.
Source: www.tctmd.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1News Releases - Anthos Therapeutics - 7 month(s) ago
Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases
Source: anthostherapeutics.comCategories: Expert Picks, Latest HeadlinesTweet-
PR from Anthos: DSMB stops trial of 1287 patients with atrial fibrillation at moderate-to-high risk of stroke due to an overwhelming reduction in composite of major and clinically relevant non-major bleeding in pts on #abelacimab vs #rivaroxaban, https://t.co/rfKTulnkC8
-
-
Mashup Score: 26
Background: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#STROKE Study of #Rivaroxaban for Cerebral Venous Thrombosis #CVT: a randomized phase II trial. #AHAJournals https://t.co/ASLugexEzz @mihill68 @SposatoL @DrMarkBoulos @AlmekhlafiMa @FouziBala @IAlhabli @vancouverstroke https://t.co/qKftvMkiH5
-
-
Mashup Score: 0
Objectives COMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery disease and sinus rhythm. Patients with diabetes are at increased risk of cardiovascular events and therefore have more to gain. Methods and results In this post-hoc analysis, we evaluated the efficacy and safety of rivaroxaban in patients with (n=2052) and without diabetes (n=2970). The primary outcome was the composite of cardiovascular death, myocardial infarction (MI) or ischaemic stroke. HRs and 95% CIs with interaction analyses were used to describe event-rates and treatment effects. Patients with diabetes had a higher prevalence of cardiovascular comorbidities (eg, hypertension, obesity) and increased incidence of cardiovascular events. Adjusted HRs for events in people with versus without diabetes were 1.34 (95% CI 1.19 to 1.50) for the primary outcome, 1.21 (95% CI
Source: bmjopen.bmj.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Cardiovascular effects of #rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without #diabetes. Find out more in this retrospective international cohort study from COMMANDER-HF: https://t.co/u6lxnBHzTs @fjpinto1960 https://t.co/0dfxxzB4kw
-
-
Mashup Score: 0DOAC Study Finds Increased Myocardial Infarction Risk for Dabigatran | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination February 1, 2023 Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. There are no randomized clinical trial results comparing the relative safety and efficacy of…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Among patients with #atrial #fibrillation taking #DOACS, #rivaroxaban was found to be associated with higher major bleeding rates, while #dabigatran was associated with twofold higher rates of #myocardial #infarction https://t.co/YfOtN9QdK4
-
-
Mashup Score: 1No differences in bleeding, thromboembolic events with DOACs vs. warfarin after surgery - 1 year(s) ago
Patients who received apixaban or rivaroxaban after cardiac surgery were no more likely to experience major bleeding or thromboembolic events compared with patients who received warfarin after surgery, data from a single-center study show.“Landmark studies of the major direct oral anticoagulant agents were not designed to study outcomes in cardiac surgery patients,” Alan J. Rozycki,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients who received #apixaban or #rivaroxaban after cardiac surgery were no more likely to experience major bleeding or thromboembolic events compared with patients who received warfarin after surgery @OSUWexMed @JCardSurg #cardiotwitter https://t.co/1T2BwzvtFR
-
-
Mashup Score: 1
Why is this study important? Outpatients with Covid-19 infection during the pandemic were suspected to be at increased risk for venous and arterial thrombotic events. In fact, histopathological evidence suggests that part of the worsening of lung function in these patients leading to their hospitalization is due to microvascular and macrovascular vascular thrombosis. Thus, there has been a…
Source: scai.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
8/9 PREVENT-HD – #Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial ➡️ https://t.co/LrKi4YyshZ https://t.co/Ti4dzJFZIG
-
-
Mashup Score: 0Anticoagulation Again Flops for Outpatient COVID-19 - 1 year(s) ago
Largest-yet RCT shows no benefit for non-hospitalized symptomatic patients despite elevated risk
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
For outpatient COVID-19, prophylactic anticoagulation with #rivaroxaban (#Xarelto) did not improve outcomes in elevated thrombotic risk patients, Gregory Piazza, MD, of @BrighamWomens and @HarvardMed, reported at #AHA22. https://t.co/A1fDfyGrRI
-
-
Mashup Score: 0Rivaroxaban after laparoscopic cancer surgery - 2 year(s) ago
Reduction of thrombotic risk after surgery is a long-established clinical practice standard, but evidence is lacking in some specific settings. In this issue of
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Rivaroxaban after #Laparoscopic cancer surgery A wonderful review article showing good VTE prevention w/ Rivaroxaban following this type of surgery! 👉https://t.co/325wSlDOSc @BloodJournal @GeraldSoff #CancerSurgery https://t.co/n2J336Xa2h
-
-
Mashup Score: 2
Background: Although apixaban and rivaroxaban are commonly used in patients with atrial fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 drugs in these patients. Objective: To emulate a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and VHD. Design: New-user, active comparator, cohort study design. Setting:…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New from @PennMedicine: Comparison of blood thinners finds important differences. #apixaban associated with lower rate of ischemic stroke, embolism, intracranial/GI bleeding compared with #rivaroxaban in patients with #afib and valvular #heartdisease: https://t.co/y7rrlD0jb9 https://t.co/MMQpbQW4oQ
-
The novel factor XI/XIa inhibitor #abelacimab, being studied in the AZALEA-TIMI 71 trial, lowered a composite of major and clinically relevant nonmajor bleeding compared with #rivaroxaban in patients with #AFib at moderate-to-high risk of stroke https://t.co/2vbyLQskYV https://t.co/3cUsdO2y5d